748 related articles for article (PubMed ID: 17204951)
1. Effect of omeprazole on acid gastroesophageal reflux and gastric acidity in preterm infants with pathological acid reflux.
Omari TI; Haslam RR; Lundborg P; Davidson GP
J Pediatr Gastroenterol Nutr; 2007 Jan; 44(1):41-4. PubMed ID: 17204951
[TBL] [Abstract][Full Text] [Related]
2. Twenty-four-hour esophageal impedance-pH monitoring in healthy preterm neonates: rate and characteristics of acid, weakly acidic, and weakly alkaline gastroesophageal reflux.
López-Alonso M; Moya MJ; Cabo JA; Ribas J; del Carmen Macías M; Silny J; Sifrim D
Pediatrics; 2006 Aug; 118(2):e299-308. PubMed ID: 16831894
[TBL] [Abstract][Full Text] [Related]
3. Persistent acid secretion during omeprazole therapy: a study of gastric acid profiles in patients demonstrating failure of omeprazole therapy.
Leite LP; Johnston BT; Just RJ; Castell DO
Am J Gastroenterol; 1996 Aug; 91(8):1527-31. PubMed ID: 8759655
[TBL] [Abstract][Full Text] [Related]
4. Control of esophageal and intragastric pH with compounded and manufactured omeprazole in patients with reflux esophagitis: a pilot study.
Moretzsohn LD; Carvalho EB; Franco JD; Soares MP; Brito EM; Belarmino K; Coelho LG
Can J Clin Pharmacol; 2009; 16(1):e264-72. PubMed ID: 19383986
[TBL] [Abstract][Full Text] [Related]
5. Comparison of gastric pH with omeprazole magnesium 20.6 mg (Prilosec OTC) o.m. famotidine 10 mg (Pepcid AC) b.d. and famotidine 20 mg b.d. over 14 days of treatment.
Miner PB; Allgood LD; Grender JM
Aliment Pharmacol Ther; 2007 Jan; 25(1):103-9. PubMed ID: 17229225
[TBL] [Abstract][Full Text] [Related]
6. Prolonged ambulatory pH monitoring in patients with persistent gastroesophageal reflux disease symptoms: testing while on therapy identifies the need for more aggressive anti-reflux therapy.
Katzka DA; Paoletti V; Leite L; Castell DO
Am J Gastroenterol; 1996 Oct; 91(10):2110-3. PubMed ID: 8855731
[TBL] [Abstract][Full Text] [Related]
7. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors.
Peghini PL; Katz PO; Bracy NA; Castell DO
Am J Gastroenterol; 1998 May; 93(5):763-7. PubMed ID: 9625124
[TBL] [Abstract][Full Text] [Related]
8. Double-blind placebo-controlled trial of omeprazole in irritable infants with gastroesophageal reflux.
Moore DJ; Tao BS; Lines DR; Hirte C; Heddle ML; Davidson GP
J Pediatr; 2003 Aug; 143(2):219-23. PubMed ID: 12970637
[TBL] [Abstract][Full Text] [Related]
9. pH, healing rate, and symptom relief in patients with GERD.
Huang JQ; Hunt RH
Yale J Biol Med; 1999; 72(2-3):181-94. PubMed ID: 10780580
[TBL] [Abstract][Full Text] [Related]
10. [Non-erosive gastroesophageal reflux disease. Incidence of clinical forms, characteristics of esophageal exposure to acid and symptomatic correlations].
Soto Pérez JC; Icaza ME; Vargas F; Valdovinos Díaz MA
Rev Gastroenterol Mex; 2003; 68(2):113-9. PubMed ID: 15127647
[TBL] [Abstract][Full Text] [Related]
11. A comparative pharmacodynamic study of IY-81149 versus omeprazole in patients with gastroesophageal reflux disease.
Periclou AP; Goldwater R; Lee SM; Park DW; Kim DY; Cho KD; Boileau F; Jung WT
Clin Pharmacol Ther; 2000 Sep; 68(3):304-11. PubMed ID: 11014412
[TBL] [Abstract][Full Text] [Related]
12. Clinical trial: the effects of adding ranitidine at night to twice daily omeprazole therapy on nocturnal acid breakthrough and acid reflux in patients with systemic sclerosis--a randomized controlled, cross-over trial.
Janiak P; Thumshirn M; Menne D; Fox M; Halim S; Fried M; Brühlmann P; Distler O; Schwizer W
Aliment Pharmacol Ther; 2007 Nov; 26(9):1259-65. PubMed ID: 17944740
[TBL] [Abstract][Full Text] [Related]
13. Nocturnal gastric acid breakthrough is not associated with night-time gastroesophageal reflux in GERD patients.
Weigt J; Kandulski A; Büsch F; Malfertheiner P
Dig Dis; 2009; 27(1):68-73. PubMed ID: 19439964
[TBL] [Abstract][Full Text] [Related]
14. Correlation between gastric pH and gastro-oesophageal reflux contents: ambulatory pH-impedance monitoring results.
Roman S; Serraj I; Damon H; Mion F
Neurogastroenterol Motil; 2007 Jul; 19(7):562-8. PubMed ID: 17593137
[TBL] [Abstract][Full Text] [Related]
15. Stability of gastric secretory inhibition during 6-month treatment with omeprazole in patients with gastroesophageal reflux disease.
Tefera S; Hatlebakk JG; Berstad A
Am J Gastroenterol; 2001 Apr; 96(4):969-74. PubMed ID: 11316213
[TBL] [Abstract][Full Text] [Related]
16. 24-h pH monitoring is necessary to assess acid reflux suppression in patients with Barrett's oesophagus undergoing treatment with proton pump inhibitors.
Ortiz A; Martínez de Haro LF; Parrilla P; Molina J; Bermejo J; Munitiz V
Br J Surg; 1999 Nov; 86(11):1472-4. PubMed ID: 10583299
[TBL] [Abstract][Full Text] [Related]
17. Impact of Helicobacter pylori eradication on the anti-secretory efficacy of lansoprazole in gastroesophageal reflux disease patients.
Giral A; Celikel CA; Ozdogan O; Tözün N; Ulusoy NB; Kalayci C
J Gastroenterol Hepatol; 2005 Dec; 20(12):1886-91. PubMed ID: 16336449
[TBL] [Abstract][Full Text] [Related]
18. Omeprazole as a diagnostic tool in gastroesophageal reflux disease.
Schenk BE; Kuipers EJ; Klinkenberg-Knol EC; Festen HP; Jansen EH; Tuynman HA; Schrijver M; Dieleman LA; Meuwissen SG
Am J Gastroenterol; 1997 Nov; 92(11):1997-2000. PubMed ID: 9362179
[TBL] [Abstract][Full Text] [Related]
19. Does the presence of a hiatal hernia affect the efficacy of the reflux inhibitor baclofen during add-on therapy?
Beaumont H; Boeckxstaens GE
Am J Gastroenterol; 2009 Jul; 104(7):1764-71. PubMed ID: 19491837
[TBL] [Abstract][Full Text] [Related]
20. Analysis of the acidity index and integrated intragastric acidity in 645 patients presenting with gastroesophageal reflux disease symptoms.
Blonski WC; Shih GL; Brensinger CM; Katzka DA; Metz DC
Scand J Gastroenterol; 2006 Apr; 41(4):382-9. PubMed ID: 16635904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
